

AMENDMENT TRANSMITTAL LETTER (Small Entity)

Applicant(s): Habib Zaghouani

Docket No.

ALLIA.143A

Serial No. OIPE
08/179,767 70572Filing Date
January 7, 1997Examiner
J. ReevesGroup Art Unit
1806

Invention: Compounds, Compositions and Methods for the Endocytic Presentation of Immunosuppressive Factors

TO THE ASSISTANT COMMISSIONER FOR PATENTS:

Transmitted herewith is an amendment in the above-identified application.

- Small Entity status of this application has been established under 37 CFR 1.27 by a verified statement previously submitted.
- A verified statement to establish Small Entity status under 37 FR 1.27 is enclosed.

The fee has been calculated and is transmitted as shown below.

CLAIMS AS AMENDED

	CLAIMS REMAINING AFTER AMENDMENT	HIGHEST # PREV. PAID FOR	NUMBER EXTRA CLAIMS PRESENT	RATE	ADDITIONAL FEE
TOTAL CLAIMS	65 -	65 =	0 x	\$11.00	\$0.00
INDEP. CLAIMS	8 -	8 =	0 x	\$40.00	\$0.00
Multiple Dependent Claims (check if applicable) <input type="checkbox"/>					\$0.00
TOTAL ADDITIONAL FEE FOR THIS AMENDMENT					\$0.00

- No additional fee is required for amendment.
- Please charge Deposit Account No. in the amount of
A duplicate copy of this sheet is enclosed.
- A check in the amount of to cover the filing fee is enclosed.
- The Commissioner is hereby authorized to charge payment of the following fees associated with this communication or credit any overpayment to Deposit Account No. 01-1008
A duplicate copy of this sheet is enclosed.
- Any additional filing fees required under 37 C.F.R. 1.16.
- Any patent application processing fees under 37 CFR 1.17.

RECEIVED
AUG 11 1997
GROUP 1800

Signature

Dated: 2 September 1997


I certify that this document and fee is being deposited on 2 September 1997 with the U.S. Postal Service as first class mail under 37 C.F.R. 1.8 and is addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

Signature of Person Mailing Correspondence

Christopher A. Dayton

Typed or Printed Name of Person Mailing Correspondence

CC:



ALLIA. 143A

43A
SEP 05 1997

PATENT

#6
Denny
9/19/97

~~SEARCHED~~ IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RESPONSE TO REQUIREMENT FOR RESTRICTION

Assistant Commissioner for Patents
Washington, D.C. 20231

RECEIVED
AUG 11 1997
GROUP 1800

Dear Sir:

Claims 1-65 are currently pending in the above-identified patent application. The claims generally relate to compounds and compositions for regulation of the immune system, their use and their formation.

In a requirement for restriction dated 1 August 1997, it is alleged that the claims, as presently written, are directed to several inventions. As set forth in the subject Official Action, Group I (claims 1-11, 22-29) is drawn to an Fc receptor ligand and immunosuppressive factor fusion, classified in class 514, subclass 12. The claims of Group II (claims 12-21), are held to be directed to recombinant methods of making immunomodulating compounds classified in class 435, subclass 69.6. Group III (claims 30-38) is held to comprise claims directed to methods for